2- (6- ((2- (3- hydroxypropyl)- 5- methylphenylamino)methyl)- 2- (3- morpholin- 4- ylpropylamino)benzoimidazol- 1- ylmethyl)- 6- methylpyridin- 3- ol
inhibits respiratory syncytial virus fusion; structure in first source
Also Known As:
TMC 353121; TMC-353121; TMC353121
Networked: 2
relevant articles (1 outcomes,
1 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
1. | Andries, Koen:
1 article
(01/2015)
|
2. | Bonfanti, Jean-François:
1 article
(01/2015)
|
3. | De Jonghe, Sandra:
1 article
(01/2015)
|
4. | Ispas, Gabriela:
1 article
(01/2015)
|
5. | Koul, Anil:
1 article
(01/2015)
|
6. | Rouan, Marie-Claude:
1 article
(01/2015)
|
7. | Roymans, Dirk:
1 article
(01/2015)
|
8. | Sanders-Beer, Brigitte:
1 article
(01/2015)
|
9. | Sheehan, Jennifer:
1 article
(01/2015)
|
10. | Simmen, Kenneth:
1 article
(01/2015)
|
Related Diseases
1. | Infections
01/01/2015
- " Study 1 evaluated the prophylactic and therapeutic efficacy of TMC353121 at a target plasma level of 50 ng/mL (n=15; Group 1: prophylactic arm [Px50], 0.033 mg/mL TMC353121, flow rate 2.5 mL/kg/h from 24 hours pre-infection to 10 days; Group 2: therapeutic arm [Tx50], 0.033 mg/mL TMC353121 from 24 hours postinfection to 8 days; Group 3: control [Vh1] vehicle, 24 hours post-infection to 8 days). " 01/01/2015
- " Study 2 evaluated the prophylactic efficacy of TMC353121 at target plasma levels of 5 and 500 ng/mL (n=12; Group 1: prophylactic 5 arm [Px5], 0.0033 mg/mL TMC353121, flow rate 2.5 mL/kg/h from 72 hours pre-infection to 14 days; Group 2: prophylactic 500 arm [Px500], 0.33 mg/mL TMC353121; Group 3: control [Vh2] vehicle, 14 days). " 08/01/2011
- " At doses of 0.25-10 mg · kg(-1), TMC353121 significantly reduced viral load, bronchoalveolar lavage cell accumulation and the severity of lung histopathological change after infection. " 08/01/2011
- " The drug is a small molecule (TMC353121) discovered by screening for fusion inhibitory properties against RSV in a cellular infection model. "
|
2. | Respiratory Syncytial Virus Infections
|
3. | Pneumonia (Pneumonitis)
|
|
Related Drugs and Biologics